Oncotarget

Dr. Reshma Sundar and Dr. Marene Landström from the Department of Medical Biosciences at Umeå University in Sweden discuss their experience publishing the research paper, “Pro-invasive properties of Snail1 are regulated by sumoylation in response to TGFβ stimulation in cancer”, with Oncotarget in 2017.

DOI - https://doi.org/10.18632/oncotarget.20097

Correspondence to - Marene Landström - [email protected]

Keywords - signal transduction, tumor biology, Snail1, sumoylation, prostate cancer

About Oncotarget

Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with us:

SoundCloud - https://soundcloud.com/oncotarget

Facebook - https://www.facebook.com/Oncotarget/

Twitter - https://twitter.com/oncotarget

Instagram - https://www.instagram.com/oncotargetjrnl/

YouTube - https://www.youtube.com/c/OncotargetYouTube/

LinkedIn - https://www.linkedin.com/company/oncotarget

Pinterest - https://www.pinterest.com/oncotarget/

Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com

Media Contact

18009220957

Dr. Michael Andreeff with the Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, talks about his experience publishing "Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia" with Oncotarget in 2017.

DOI - https://doi.org/10.18632/oncotarget.19042

Correspondence to - Michael Andreeff - [email protected]

Keywords - AML, microenvironment, GEP, stroma, genotype

About Oncotarget

Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with us:

SoundCloud - https://soundcloud.com/oncotarget

Facebook - https://www.facebook.com/Oncotarget/

Twitter - https://twitter.com/oncotarget

Instagram - https://www.instagram.com/oncotargetjrnl/

YouTube - https://www.youtube.com/c/OncotargetYouTube/

LinkedIn - https://www.linkedin.com/company/oncotarget

Pinterest - https://www.pinterest.com/oncotarget/

Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com

Media Contact

18009220957

Dr. John R. Hawse with the Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, talking about his experience publishing "ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer" with Oncotarget in 2017.

DOI - https://doi.org/10.18632/oncotarget.21787

Correspondence to - John R. Hawse - [email protected]

Keywords - TNBC, ERβ, cell cycle, CDK, estrogen

About Oncotarget

Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with us:

SoundCloud - https://soundcloud.com/oncotarget

Facebook - https://www.facebook.com/Oncotarget/

Twitter - https://twitter.com/oncotarget

Instagram - https://www.instagram.com/oncotargetjrnl/

YouTube - https://www.youtube.com/c/OncotargetYouTube/

LinkedIn - https://www.linkedin.com/company/oncotarget

Pinterest - https://www.pinterest.com/oncotarget/

Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com

Media Contact

18009220957

Dr. Sandip Pravin Patel, Dr. Karen Yun and Dr. Karen Mccowen from the University of California San Diego, discuss a research paper they co-authored that was published by Oncotarget in Volume 11, Issue 28, entitled, “Rapid onset type 1 diabetes with anti-PD-1 directed therapy.”

DOI - https://doi.org/10.18632/oncotarget.27665

Correspondence to - Sandip Pravin Patel - [email protected]

Abstract

Type 1 diabetes is a rare immune-related adverse event (irAE) caused by checkpoint inhibitors with serious risk for diabetic ketoacidosis (DKA). Using our electronic medical record, we identified 1327 adult patients who received PD-(L)1 or CTLA-4 inhibitors from 2013 to 2018. Of the patients who received immunotherapy, 5 (0.38%) patients were found to have type 1 diabetes, all of whom presented with DKA requiring insulin at 20 to 972 days from their first anti-PD-(L)1 dose. All patients were treated with anti-PD-1 therapy (nivolumab or pembrolizumab). Four patients had new onset diabetes with mean HbA1c of 9.1% on DKA presentation and persistent elevations over time. Two patients who tested positive for glutamic acid decarboxylase (GAD) antibodies presented with DKA at 20 and 106 days from first anti-PD-1 administration whereas patients who were autoantibody negative had DKA more than a year later. Type 1 diabetes occurs within a wide time frame after anti-PD-1 initiation and commences with an abrupt course. Our case series suggests that monitoring glycemia in patients on PD-1 inhibitors is not predictive for diabetes occurrence. GAD autoantibodies could portend earlier onset for diabetes, although further prospective studies are needed to elucidate their diagnostic utility and contribution in therapeutic interception.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27665

Press release - https://www.oncotarget.com/index.php?journal=oncotarget&page=news&op=press&item=oncotarget-rapid-onset-type-1-diabetes-with-anti-pd-1-directed-therap

Keywords - type 1 diabetes, diabetic ketoacidosis (DKA), immune-related adverse event (irAE), immunotherapy, PD-1 inhibitors

About Oncotarget

Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with us:

SoundCloud - https://soundcloud.com/oncotarget

Facebook - https://www.facebook.com/Oncotarget/

Twitter - https://twitter.com/oncotarget

Instagram - https://www.instagram.com/oncotargetjrnl/

YouTube - https://www.youtube.com/c/OncotargetYouTube/

LinkedIn - https://www.linkedin.com/company/oncotarget

Pinterest - https://www.pinterest.com/oncotarget/

Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com

Media Contact

18009220957

Dr. Sridhar Mani from Medicine and Genetics of The Albert Einstein College of Medicine, Bronx, NY, details his editorial published by Oncotarget in Volume 11, Issue 19, entitled, “Microbial metabolite mimicry: one step closer to drug discovery.”

DOI - https://doi.org/10.18632/oncotarget.27591

Correspondence to - Sridhar Mani - [email protected]

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27591

Keywords - microbial metabolites, inflammation, IBD, mimicry, drugs

About Oncotarget

Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget

Facebook - https://www.facebook.com/Oncotarget/

Twitter - https://twitter.com/oncotarget

Instagram - https://www.instagram.com/oncotargetjrnl/

YouTube - https://www.youtube.com/c/OncotargetYouTube/

LinkedIn - https://www.linkedin.com/company/oncotarget

Pinterest - https://www.pinterest.com/oncotarget/

Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957

Head and neck cancer is a group of various tumors located in the oral cavity, oropharynx, larynx, and hypopharynx. Head and neck cell squamous-cell carcinomas (HNSCC) often result from tobacco use or human papillomavirus (HPV+) infection. In locally advanced HNSCC, the current therapies used are combined surgery, radiotherapy and chemotherapy. Despite the use of traditional treatments, up to 50% of patients relapse due to the increase in mutational burden as HNSCC advances. Few studies have investigated the therapeutic potential of neoantigens in HNSCC tumors.

“Prior work has characterized changes in the mutation burden between primary and recurrent tumors; however, little work has characterized the changes in neoantigen evolution.”

Neoantigens are new proteins/antigens that form on cancer cells after mutations occur in the tumor DNA. Certain neoantigens can promote anti-tumor immune responses and are potentially capable of controlling tumor progression. In an effort to characterize genomic and neoantigen changes in patients with HNSCC, researchers—from Washington University in St. Louis, Columbia University, St. Louis Children’s Hospital, and Siteman Cancer Center—investigated 23 paired primary and recurrent HNSCC tumors. Their paper, entitled, “Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma,” was chosen as the cover paper for Oncotarget’s Volume 12, Issue #6.

Full blog -https://www.oncotarget.org/2022/01/13/primary-versus-metastatic-head-and-neck-tumors/

Press release - https://www.oncotarget.com/news/pr/genomic-and-neoantigen-evolution-in-head-and-neck-squamous-cell-carcinoma/

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27907

DOI - https://doi.org/10.18632/oncotarget.27907

Full text - https://www.oncotarget.com/article/27907/text/

Correspondence to - Brian A. Van Tine - [email protected]

Keywords - head and neck squamous cell carcinoma, neoantigens, mutational evolution, tumor relapse, immune cell infiltration

About Oncotarget:

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit www.oncotarget.com or follow us:

SoundCloud - @oncotarget

Facebook - www.facebook.com/Oncotarget/

Twitter - twitter.com/oncotarget

LinkedIn - www.linkedin.com/company/oncotarget

Instagram - www.instagram.com/oncotargetjrnl/

YouTube - www.youtube.com/OncotargetYouTube

Pinterest - www.pinterest.com/oncotarget/

Reddit - www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957x105

BUFFALO, NY, January 6, 2022 – Since its inception in 2010, Oncotarget has operated as a traditional-style journal that publishes online page numbered issues of peer-reviewed papers. Final paginated issues were then released in their permanent form to Pubmed.

As of 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form. This means that qualified, rigorously peer-reviewed articles will be published online as soon as they are in their fully formatted and final version of record. With continuous publication, articles posted online are complete with citation details and are available in full text html and PDF formats. Additionally, research papers will appear on PubMed quickly—just days after the papers are published by Oncotarget.

Why the change? In an increasingly digital world, the open-access continuous publishing model is ideal for authors, researchers and overall readership. Continuous publishing allows for faster research dissemination, citation and clinical application, compared to a traditional format.

Oncotarget is committed to doing our part to ensure that research is available to the biomedical community as quickly as possible, while maintaining high standards of quality.

To learn more about Oncotarget, visit Oncotarget.com or connect with us on social media:

Twitter – https://twitter.com/Oncotarget

Facebook – https://www.facebook.com/Oncotarget

YouTube – www.youtube.com/c/OncotargetYouTube

Instagram – https://www.instagram.com/oncotargetjrnl/

LinkedIn – https://www.linkedin.com/company/oncotarget/

Pinterest – https://www.pinterest.com/oncotarget/

LabTube – https://www.labtube.tv/channel/MTY5OA

About Impact Journals (Oncotarget’s publisher):

Impact Journals is a New York-based open-access publisher with a mission to provide scientists with the opportunity to share their exceptional discoveries, and to present vital findings from different fields of biomedical science. Our goal is life without disease.

For media inquiries, please contact [email protected].

Statistics from the American Cancer Society indicate that endometrial cancer (EC) is on the rise among women in the United States. While it more commonly affects older women, researchers are finding that EC is the only gynecological cancer today increasing in incidence and mortality among younger women. Not to be confused with the benign condition of endometriosis, EC tumors are highly heterogeneous and are a challenge to diagnose and treat. Since these heterogeneous tumors also develop in differential growing environments, most studies that use EC cell lines to diagnose patients or develop treatments do not translate to efficacy in vivo.

“Current methodologies for diagnosis and treatment rely on the use of cell lines as models for tumor biology. However, due to inherent heterogeneity and differential growing environments between cell lines and tumors, these comparative studies have found little parallels in molecular signatures.”

In a new study, researchers from the Uniformed Services University of the Health Sciences and the National Institutes of Health compared signaling pathways and genes among EC cell lines and tumors in The Cancer Genome Atlas (TCGA). Their goal was to identify parallels between cell lines and tumors that may be associated with regulating EC transformation and progression. In December 2021, their research paper was published as the cover of Oncotarget’s Volume 12, Issue 26, and entitled, “Comparative transcriptome analysis between patient and endometrial cancer cell lines to determine common signaling pathways and markers linked to cancer progression”.

“Identifying mutually dysregulated biomarkers and signaling pathways in cell lines and tumors can advantageously provide a more expedient method for studying mechanisms in cancer biology.”

Full blog - https://www.impactjournals.com/journals/blog/oncotarget/new-study-biomarkers-linked-to-the-progression-of-endometrial-cancer/

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28161

DOI - https://doi.org/10.18632/oncotarget.28161

Full text - https://www.oncotarget.com/article/28161/text/

Correspondence to - T. John Wu - [email protected]

Keywords - endometrial cancer, cancer stage, comparative transcriptome analysis, signaling pathways, normalization

About Oncotarget

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget

Facebook - https://www.facebook.com/Oncotarget/

Twitter - https://twitter.com/oncotarget

Instagram - https://www.instagram.com/oncotargetjrnl/

YouTube - https://www.youtube.com/c/OncotargetYouTube/

LinkedIn - https://www.linkedin.com/company/oncotarget

Pinterest - https://www.pinterest.com/oncotarget/

Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957

Oncotarget published "Host targeted antiviral (HTA): functional inhibitor compounds of scaffold protein RACK1 inhibit herpes simplex virus proliferation" which reported that due to the small number of molecular targets in viruses and the rapid evolution of viral genes, it is very challenging to develop specific antiviral drugs.

In addition, HIV-1 and Herpes Simplex virus are known to use IRES as well. By utilizing the crystal structure of the RACK1A protein from the model plant Arabidopsis and using a structure based drug design method, dozens of small compounds were identified that could potentially bind to the experimentally determined functional site of the RACK1A protein.

Dr. Sivanesan Dakshanamurthy from The Georgetown University Medical Center, Dr. Qiyi Tang from The Howard University College of Medicine and Dr. Hemayet Ullah from Howard University said, "With the small number of molecular targets in viruses and the rapid evolution of viral genes, it is very challenging to develop specific antiviral drugs."

Full press release - https://www.oncotarget.com/news/pr/functional-inhibitor-compounds-inhibit-herpes-simplex-virus-proliferation/

DOI - https://doi.org/10.18632/oncotarget.26907

Full text - https://www.oncotarget.com/article/26907/text/

Correspondence to - Sivanesan Dakshanamurthy - [email protected], Qiyi Tang - [email protected], and Hemayet Ullah - [email protected]

Keywords - host targeted antiviral (HTA), herpes simplex virus (HSV), receptor for activated C kinase 1 (RACK1), RACK1 inhibitor, internal ribosomal entry site (IRES)

About Oncotarget

Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget

Facebook - https://www.facebook.com/Oncotarget/

Twitter - https://twitter.com/oncotarget

LinkedIn - https://www.linkedin.com/company/oncotarget

Pinterest - https://www.pinterest.com/oncotarget/

Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957x105

The cover for issue 29 of Oncotarget features Figure 2, "Categorisation of samples analysed," from Laes, et al.

- OncoDNA treatment recommendation followed in 60% of cases

- 93% of treatment decisions were made based on a holistic approach combining next generation sequencing (NGS) and multiple biomarker analysis provided by OncoDNA

- 27% of late-stage patients treated with OncoDNA-recommended therapies had overall survival less than 12 months, compared to a typical average of no more than six months

Gosselies, Belgium - April 17, 2018: OncoDNA ("OncoDNA or "the Company"), the healthcare technology company that collates and translates complex cancer biomarker data to make precision medicine a reality, is pleased to announce the publication of a study in the journal Oncotarget evaluating the utility of OncoDNA's comprehensive biomarker analysis and interpretation services in clinical settings.

The study, published online today and titled "The clinical impact of using complex molecular profiling strategies in routine oncology practice", found that combining advanced, comprehensive testing of cancer biomarkers with OncoDNA's proprietary cancer treatment knowledge database can enable oncologists to make better treatment decisions for their patients. This is because OncoDNA's testing combines immunohistochemistry, next generation sequencing (NGS), and other tests including inherited heart condition testing, DNA methylation, and microsatellite instability (MSI) testing, rather than the industry standard of NGS testing alone.

Full press release - https://www.oncotarget.com/news/pr/oncodna-announces-publication-of-peer-reviewed-study-in-oncotarget-assessing-the-utility-of-its-unique-biomarker-analysis-and-interpretation-platform-in-clinical-decision-making/

DOI - https://doi.org/10.18632/oncotarget.24757

Full text - https://www.oncotarget.com/article/24757/text/

Correspondence to - Jean-François Laes - [email protected]

Keywords - molecular profiling, solid tumour, precision medicine, next-generation sequencing, therapeutic decision making in oncology

About Oncotarget

Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget

Facebook - https://www.facebook.com/Oncotarget/

Twitter - https://twitter.com/oncotarget

Instagram - https://www.instagram.com/oncotargetjrnl/

YouTube - https://www.youtube.com/c/OncotargetYouTube/

LinkedIn - https://www.linkedin.com/company/oncotarget

Pinterest - https://www.pinterest.com/oncotarget/

Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957